1. Serum Krebs Von Den Lungen-6 as a Biomarker for Early Detection of Bronchiolitis Obliterans Syndrome in Children Undergoing Allogeneic Stem Cell Transplantation 
Adam Gassas, Tal Schechter, Joerg Krueger, Hayley Craig-Barnes, Lillian Sung, Muhammad Ali, Sharon Dell, R. Maarten Egeler, Irina Zaidman, Nades Palaniyar 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 8, Pages (August 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
KL-6 concentrations in plasma of healthy control subjects and stem cell recipients at pre-SCT and at 1-month and 3-month post-SCT stages. (A) KL-6 is virtually undetectable in healthy control subjects. All SCT patients had elevated concentrations of KL-6 in their plasma compared with healthy control subjects at all time points (P < .01). Most patients who had elevated KL-6 either died or developed BOS. Patients who developed BOS had higher levels of KL-6 at the (A) pre-SCT stage (P < .05) and (B) 1 month post-SCT (P < .04). (C) At 3 months post-SCT the differences were not significantly different (P < .12). The variation in KL-6 at 3 months was high, and 1 patient had already started receiving treatment for BOS. Lines mark median and interquartile ranges.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Individual patient KL-6 concentrations in the plasma in (A) alive non-BOS (n = 18) and (B) alive BOS patients (n = 5). One patient (D) died from BOS and was not included. One patient (N) had not started therapy for BOS at time of data analysis. Four patients with BOS showed reduction/stabilization of KL-6 levels after starting therapy (downward arrows show time therapy started).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions